Schutzman D L, Baudhuin L M, Gatien E, Ajayi S, Wong R J
Department of Pediatrics and Adolescent Medicine, Einstein Medical Center, Philadelphia, PA, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
J Perinatol. 2017 Apr;37(4):432-435. doi: 10.1038/jp.2016.232. Epub 2016 Dec 15.
The objective of our study was to measure the effect of genetic variants of these two enzymes, UGT1A1 and SLCO1B1, in the bilirubin metabolic pathway on the degree of hyperbilirubinemia in a cohort of African-American (AA) infants from our well-baby nursery. In addition, a second objective was to document the types and frequencies of genetic variations of these enzymes in our cohort.
A prospective study of 180 AA infants from the Well Baby Nursery of an inner city community hospital, all of whose mothers were type O pos. Sixty infants were ABO-incompatible direct antiglobulin test (DAT) pos, 60 were ABO-incompatible DAT neg and 60 were type O. Blood for carboxyhemoglobin (COHb) and variants of the enzymes uridine diphosphoglucuronosyltransferase 1A1 and hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) was drawn at the time of the infants' initial bilirubin, and the infants' precise percentile on the Bhutani nomogram was calculated.
Variants in the two enzymes studied were quite common. In total, 21.1% were positive for a Gilbert phenotype, whereas an additional 42.4% were heterozygous for the *28 or *37 variant of UGT1A1. In total, 67.2% were homozygous for the *60 variant of the phenobarbital responsive enhancer module. In total, 41.1% were homozygous for the *1b variant of SLCO1B1, whereas an additional 12.7% were positive for the *4 variant of this gene. In total, 20.6% of infants had variations in both genes. Using logistic regression when COHbc was assessed with each of the different variants, only COHbc (P<0.0001 to 0.0004) was significantly associated with the level of hyperbilirubinemia as defined by the Bhutani nomogram.
Although we have found quite a large number of genetic variants of the UGT1A1 and SLCO1B1 genes in the AA population, it does not appear that they have a significant impact on the incidence of hyperbilirubinemia among this group of infants.
我们研究的目的是测量胆红素代谢途径中这两种酶,即尿苷二磷酸葡萄糖醛酸基转移酶1A1(UGT1A1)和有机阴离子转运多肽1B1(SLCO1B1)的基因变异对我们健康婴儿托儿所中一组非裔美国(AA)婴儿高胆红素血症程度的影响。此外,第二个目的是记录我们队列中这些酶基因变异的类型和频率。
对一家市中心社区医院健康婴儿托儿所的180名AA婴儿进行前瞻性研究,所有婴儿的母亲均为O型阳性。60名婴儿ABO血型不合且直接抗球蛋白试验(DAT)阳性,60名婴儿ABO血型不合但DAT阴性,60名婴儿为O型。在婴儿首次检测胆红素时采集血样检测碳氧血红蛋白(COHb)以及尿苷二磷酸葡萄糖醛酸基转移酶1A1和肝脏溶质载体有机阴离子转运体1B1(SLCO1B1)的基因变异,并计算婴儿在布塔尼列线图上的确切百分位数。
所研究的两种酶的变异相当常见。总体而言,21.1%的婴儿具有吉尔伯特表型阳性,另外42.4%的婴儿为UGT1A1基因28或37变异的杂合子。总体而言,67.2%的婴儿为苯巴比妥反应增强子模块60变异的纯合子。总体而言,41.1%的婴儿为SLCO1B1基因1b变异的纯合子,另外12.7%的婴儿该基因*4变异阳性。总体而言,20.6%的婴儿两个基因都有变异。当用每种不同变异评估COHbc时,使用逻辑回归分析,只有COHbc(P<0.0001至0.0004)与布塔尼列线图定义的高胆红素血症水平显著相关。
尽管我们在AA人群中发现了大量UGT1A1和SLCO1B1基因的变异,但这些变异似乎对这组婴儿高胆红素血症的发生率没有显著影响。